A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)

LESSONS LEARNED: Apatinib has potential as an effective and safe second‐line or higher treatment for patients with chemotherapy‐refractory esophageal squamous cell carcinoma (ESCC). Clinical safety is of potential concern when administering apatinib to patients with uncontrolled esophageal lesions o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Li, Chen, Yun, Liu, Qi, Liang, Fei, Wang, Shengping, Liu, Quan, Yu, Hui, Wu, Xianghua, Zhang, Junhua, Deng, Jiaying, Ai, Dashan, Zhu, Zhengfei, Nie, Yongzhan, Zhao, Kuaile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176978/
https://www.ncbi.nlm.nih.gov/pubmed/33393167
http://dx.doi.org/10.1002/onco.13668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176978/
https://www.ncbi.nlm.nih.gov/pubmed/33393167
http://dx.doi.org/10.1002/onco.13668

Ejemplares similares